Inactivated and adjuvanted influenza vaccines

Current Topics in Microbiology and Immunology

Volumn 386, Issue , 2015, Pages 151-180

  Giudice, Giuseppe Del ^a   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AF 03; ALPHA GALACTOSYLCERAMIDE; ALPHA TOCOPHEROL; AS 03; AS 03A; AS 03B; BUFFER; GLYCEROL; IC 31; INACTIVATED VACCINE; INFLUENZA VACCINE; ISCOM; LIPOSOME; MANNITOL; MATRIX M; MIFAMURTIDE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYINOSINIC POLYCYTIDYLIC ACID; POLYOXYETHYLENE DERIVATIVE; SORBITAN OLEATE; SQUALENE; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 5 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; WATER OIL CREAM; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE;

ARTICLE; DRUG EFFICACY; ECCHYMOSIS; EPIDEMIC; ERYTHEMA; GERIATRIC PATIENT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PANDEMIC; PREGNANT WOMAN; PRIORITY JOURNAL; PRURITUS; PUBLIC HEALTH; SINGLE DRUG DOSE; SKIN INDURATION; SWELLING; VACCINE PRODUCTION; ANIMAL; DRUG COMBINATION; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANIMALS; DRUG COMBINATIONS; HUMANS; INFLUENZA VACCINES; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 84921759003     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2014_406     Document Type: Article

References (170)

1. Alberini I, Del Tordello E, Fasolo A, Temperton N, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Giuseppe Del Giudice G, Donnelly J, Rappuoli R, Capecchi B (2009) Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27:5998–6003
2. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P (2008) Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and hemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26:1525–1529
3. Ansaldi F, Zancolli F, Durando P, Montomoli E, Sticchi L, Giuseppe Del Giudice G, Icardi G (2010) Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partical matching between vaccine strain and clinical isolates. Vaccine 28:4123–4129
4. Baldo V, Baldovin T, Floreani A, Minuzzo M, Trivello R (2006) Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 21:843–845
5. Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, Busana MC, Bertoncello C, Trivello R (2010) Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010:517198. doi: 10.1155/2010/517198. Epub 2010 Mar 29
6. Banzhoff A, Nacci P, Podda A (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis. Gerontology 49:177–184
7. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2):e4384
8. Banzhoff A, Haertel S, Praus M (2011) Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 7:539–548
9. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ (2011) Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377:751–759
10. Beebe GW, Simon AH, Vivona S (1972) Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 95:337–346
11. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, Kollmann TR, Reed SG, McElhaney JE (2012) GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 205:466–473
12. Belshe RB (2010) The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl 4):D45–D53
13. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286–2294
14. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755–6763
15. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, Xu H, Pascual V, Banchereau J, Garcia-Sastre A, Palucka AK, Ramilo O, Ueno H (2013) Induction of ICOS + CXCR3 + CXCR5 + TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 5:176ra32
16. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E (2003) Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 69:560–567
17. Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM (2009) Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective randomized, placebo-controlled trial. J Infect Dis 200:1861–1869
18. Beran J, Peeters M, Dewé W, Raupachova J, Hobzova L, Devaster JM (2013) Immunogenicity and safety of quadrivalent versus trivalent inactivated vaccine: a randomized, controlled trial in adults. BMC Infect Dis 13:224
19. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197:667–675
20. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL (1979) Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 140:844–850
21. Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A (2010) Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28:7331–7336
22. Black S, Nicolay U, Vesikari T, Knuf M, Giuseppe Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R (2011) Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30:1081–1085
23. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, De Gregorio E, Seubert A, Wack A (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29:1812–1823
24. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O’Hagan DT, Baudner B, Seubert A (2013) The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31:3363–3369
25. Camilloni B, Neri M, Lepri E, Iorio AM (2009) Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27:4099–4103
26. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E (2012) MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 188:3088–3098
27. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852–6862
28. Centers for Disease Control (2010). Updated CDC estimates of 2009 H1N1 influenza cass, hospitalizations and deaths in the United States, April 2009–April 2010
29. Centers for Disease control (2013) Flu vaccination coverage. http://www.cdc.gov/flu/fluvaxview/coverage-1213estimates.htm. Accessed 23 Dec 2013
30. Chen WH, Cross AS, Edelman R, Sztein M, Blackwelder WC, Pasetti MF (2011) Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with standard or a high dose influenza vaccine. Vaccine 29:2865–2873
31. Christensen D, Korsholm KS, Andersen P, Agger EM (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10:513–521
32. Clements ML, Betts RF, Tierney EL, Murphy BR (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24:157-160
33. Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JAB, Evans JE, Ennis FA, Terajima M (2009) In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27:319-327
34. Committee on Infectious Diseases (2013) Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics 132:e1089-e1104
35. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143
36. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705-742
37. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R (2010) Relationship between haemagglutinin-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random effects model. BMC Med Res Methodol 10:18
38. Crowe JE Jr (2013) Universal flu vaccines: primum non nocere. Sci Transl Med 5:200fs34
39. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d’Ortho MP, Launois S, Lignot S, Bourgin P, Nogues B, Rey M, Bayard S, Scholz S, Lavault S, Tubert-Bitter P, Saussier C, Pariente A, Narcoflu-VF study group (2013) Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136:2486-2496
40. Davenport FM (1968) Antigenic enhancement of ether-extracted influenza virus vaccines by AlPO4. Proc Soc Exp Biol Med 127:587-590
41. Davenport FM, Hennessy AV, Bell JA (1962) Immunologic advantages of emulsified influenza virus vaccines. Mil Med 127:95-100
42. Davenport DM, Hennessy AV, Askin FB (1968) Lack of adjuvant effect of AlPO4 on purified influenza virus hemagglutining in man. J Immunol 100:1139-1140
43. Davis DJ, Philip RN, Bell JA, Voegel JE, Jensen DV (1961) Epidemiological studies on influenza in familiar and general population groups 1951-1956. III. Laboratory observations. Am J Hyg 73:138-147
44. De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, Mignot E (2013) CD4+ T Cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 5:216ra176
45. Giuseppe Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A (2006) An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24:3063-3065
46. Giuseppe Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R (2013) Aflunov: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 13:121-135
47. Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U (2011) Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. Vaccine 29:8696-8704
48. Dolin R (2013) The quadrivalent approach to influenza vaccination. J Infect Dis 208:539-540
49. Domachowske JB, Pankow-Culot H, Bautista M, Geng Y, Claeys C, Peeters M, Innis BL, Jain V (2013) A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 207:1878-1887
50. Dormitzer PR, Tsai TF, Giuseppe Del Giudice G (2012) New technologies for influenza vaccines. Hum Vaccin Immunother 8:45-58
51. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, Dattilo BM, Denisova EA, De Souza I, Eickmann M, Dugan VG, Ferrari A, Gomila RC, Han L, Judge C, Mane S, Matrosovich M,Merryman C, Palladino G, Palmer GA, Spencer T, Strecker T, Trusheim H, Uhlendorff J, Wen Y, Yee AC, Zaveri J, Zhou B, Becker S, Donabedian A, Mason PW, Glass JI, Rappuoli R, Venter JC (2013) Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 5:185ra68
52. Engelhardt OG (2013) Many ways to make an influenza virus–review of influenza virus reverse genetics methods. Influenza Other Respir Viruses 7:249–256
53. Esposito S, Tagliabue C, Tagliaferri L, Semino M, Longo MR, Principi N (2012) Preventing influenza in younger children. Clin Microbiol Infect 18(Suppl 5):42–49
54. European Medicines Agency (2008) Optaflu. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000758/human_med_000952.jsp&mid= WC0b01ac058001d124. Accessed 23 Dec 2013
55. European Medicines Agency (2009) Celvaplan. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000982/human_med_000690.jsp&mid= WC0b01ac058001d124. Accessed 23 Dec 2013
56. Fiore AE, Bridges CB, Cox NJ (2009) Seasonal influenza vaccines. Curr Top Microbiol Immunol 333:43–82
57. Food and Drug Administration (2012) Flucelvax. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm. Accessed 23 Dec 2013
58. Food and Drug Administration (2013) Flublok. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm. Accessed 23 Dec 2013
59. Fries LF, Smith GE, Glenn GM (2013) A recombinant virus-like particle influenza A (H7N9) vaccine. N Engl J Med 369:2564–2566
60. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G, Abrignani S (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104:3984–3989
61. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Giuseppe Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I (2009a) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 106:7962–7967
62. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Giuseppe Del Giudice G, Castellino F (2009b) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts longterm persistence of protective antibody levels. Proc Natl Acad Sci USA 106:3877–3882
63. Garçon N, Vaughn DW, Didierlaurent AM (2012) Development and evaluation of AS03, an adjuvant system containing a-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 11:349–366
64. Gibson DG, Smith HO, Hutchison CA III, Venter JC, Merryman C (2010) Chemical synthesis of the mouse mitochondrial genome. Nat Methods 7:901–903
65. Goodwin K, Viboud C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159–1169
66. Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH (2013) Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine 31:6034–6040
67. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31:770–776
68. Hafner AM, Corthésy B, Merkle HP (2013) Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 65:1386–1399
69. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, Black HC, Goldfield M (1979) A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (Swine flu) and A/Victoria/75: Report of a study and review of the literature. Am J Public Health 69:1247–1250
70. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, Yan H, Gao ZC, Yuan Y, Strohl KP, Mignot E (2011) Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70:410-417
71. Hannoun C (2013) The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12:1085-1094
72. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter J (2012) Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 14:867-871
73. Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, Della Cioppa G (2012) Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 207(3):177.e1-8
74. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Venter JC, Dormitzer PR, Rappuoli R, Geall AJ (2013) Rapidly produced SAM vaccine against H7N9 influenza is immunogenic in mice. Emerg Microb Infect 2:e52
75. Hennessy AV, Davenport FM (1961) Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule. Public Health Rep 76:411–419
76. Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J Hyg (Lond) 70:767–777
77. Iob A, Brianti G, Zamparo E, Gallo T (2005) Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133:687-693
78. Jain V, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, Cravioto A, Yunus M, Chanthavanich P, Linkittikul K, Kurugol Z, Alhan E, Caplanusi A, Durviaux S, Boutet P, Ofori-Anyinam O, Chandrasekaran V, Dbaibo G, Innis BL (2013) Vaccine for prevention of mild and moderate-to-severe influenza in children N Engl J Med Epub. doi:10.1056/NEJMoa1215817
79. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E (2012) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 8:CD004879
80. Karlsson EA, Marcelin G, Webby RJ, Schultz-Cherry S (2012) Review on the impact of pregnancy and obesity on influenza virus infection. Influenza Other Respir Viruses 6:449–460
81. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vacvcines grown in mammalian cells or embryonated eggs. J Infect Dis 160:191-198
82. Kendal AP, Bozeman FM, Ennis FA (1980) Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 29:966-971
83. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295-2301
84. Khurana S, Suguitan A Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic tools. PLoS Med 6:e1000049. doi: 10.1371/journal.pmed.1000049
85. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Giuseppe Del Giudice G, Rappuoli R, Golding H (2010) MF59-adjuvanted vaccines expand antibody repertoires targeting protective sites of pandemic H5N1 influenza virus. Sci Transl Med 2:15ra5
86. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Giuseppe Del Giudice G, Rappuoli R, Golding H (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza viruses. Sci Transl Med 3:85ra48
87. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H (2011b) H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 85:10945–10954
88. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H (2013) Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5:200ra114
89. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V (2013) Immunogenicity, reactogenicity and safety of an an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged [18 years. BMC Infect Dis 13(1):343
90. Klucker MF, Dalençon F, Probeck P, Haensler J (2012) AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by phase inversion temperature method. J Pharm Sci 101:4490–4500
91. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Haung LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodriguez-Weber MA, de la OM, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain V (2013) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 208:544–553
92. Legrand J, Vergu E, Flahault A (2006) Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24:6605–6611
93. Leroux-Roels I, Leroux-Roels G (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8:401–423
94. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G (2008) Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 26:6614–6619
95. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198:642–649
96. Livingston BD, Higgins D, Van Nest G (2006) Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 6:335–340
97. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G (2011) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29:7826–7834
98. Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekbom A, Örtqvist Å, Persson I, Stephansson O (2013) Influenza H1N1 vaccination and adverse pregnancy outcome. Eur J Epidemiol 28:579–588
99. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ (2012) Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 176:527–533
100. Marcelin G, Sandbulte MR, Webby RJ (2012) Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 22:267–279
101. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176:6333–6339
102. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L, Influence65 study group (2013) AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13:485–496
103. McKeage K (2013) Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix quadrivalent): a review of its use in the prevention of disease caused by influenza A and B. Drugs 73:1587-1594
104. Meier S, Bel M, L’huillier A, Crisinel PA, Combescure C, Kaiser L, Grillet S, Pósfay-Barbe K, Siegrist CA; H1N1 Epidemiology Study Group of Geneva (2011) Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29:3548-3557
105. Melén K, Partinen M, Tynell J, Sillanpää M, Himanen SL, Saarenpää-Heikkilä O, Hublin C, Olsen P, Ilonen J, Nohynek H, Syrjänen R, Kilpi T, Vuorela A, Kirjavainen T, Vaarala O, Julkunen I (2013) No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS ONE 8:e68402
106. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M (2013) Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 347:f5061. doi: 10.1136/bmj.f5061
107. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, Verity C (2013) Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346:f794
108. Monto AS, Kendal AP (1973) Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1:623-625
109. Montomoli E, Capecchi B, Hoschler K (2011) Correlates of protection against influenza. In: Rappuoli R, Giuseppe Del Giudice G (eds) Influenza vaccines for the future, 2nd edn. Springer, Basel, pp 199–222
110. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M (2011) Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461-2473
111. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels G, Van Mechelen M (2011) H5N1 influenza vaccine formulated with AS03a induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31:443–454
112. Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K (2013) Adverse events after Fluzone® intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013. Vaccine 31:4984–4987
113. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O’Hagan D, Rappuoli R, De Gregorio E (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105:10501-10506
114. Moser C, Amacker M, Zurbriggen R (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10:437–446
115. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS, Hierholzer JC (1970) Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol 92:248-256
116. National Narcolepsy Study Steeting Committee Ireland (2012) Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. http://healthupdate.gov.ie/wp-content/uploads/2012/04/Final_Report_of_National_Narcolepsy_Study_Steering_Committee-latest1.pdf. Accessed 27 Dec 2013
117. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsén P, Saarenpää-Heikkilä O, Kilpi T (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7:e33536
118. O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giuseppe Del Giudice G (2013) The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12:13-30
119. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36–44
120. Oxford J, Gilbert A, Lambkin-Williams R (2011) Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic. In: Rappuoli R, Giuseppe Del Giudice G (eds) Influenza vaccines for the future, 2nd edition, Springer, Basel, pp 115–147
121. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, Nokelainen P, Alén R, Wallden T, Espo M, Rusanen H, Olme J, Sätilä H, Arikka H, Kaipainen P, Julkunen I, Kirjavainen T (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7:e33723
122. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ (2012) T-helper 1 cells elicited by H5N1 vaccination predict seroprotectioN. J Infect Dis 206:158–166
123. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G (2009) MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27:6959–6965
124. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31:5572–5578
125. Pica N, Palese P (2013) Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189–202
126. Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680
127. Poland G, Morse D (2010) Improving the public health: the US recommendation for universal influenza immunization. Vaccine 28:2799–2800
128. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T (2013) Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP + M1 vaccine. PLoS ONE 8:e62778
129. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D (2004) Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23:283–289
130. Puig-Barberà J, Díez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, Vidal DG (2007) Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25:7313–7321
131. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM (2011) Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29:5911–5918
132. Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk DP, Farkas K, de Boer NK, Sipponen T, Ellul P, Louis E, Peake ST, Kopylov U, Maul J, Makhoul B, Fiorino G, Yazdanpanah Y, Chaparro M, European Crohn’s Colitis Organisation (ECCO) (2011) H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60:456–462
133. Reed C, Metzer MI, Finelli L, Fiore A (2012) Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30:1993–1998
134. Renfrey S (1994) Watts A (1994) Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12:747–752
135. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K (2008) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26:3461–3468
136. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, Bates J, Osterhaus AD (2000) A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19:1180–1187
137. Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, Pichon Riviere A, Karolinski A; EVA Study Research Group Estudio Embarazo y Vacuna Antigripal (2013) Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ 346:f393
138. Rümke HC, Richardus JH, Rombo L, Pauksens K, Plassmann G, Durand C, Devaster JM, Dewé W, Oostvogels L (2013) Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 13:348
139. Salk JE (1953) Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in subjects two years after vaccination. JAMA 151:1169–1175
140. Salk JE, Bailey ML, Laurel AM (1952) The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am J Hyg 55:439–456
141. Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, Research Network CI (2013) Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: Results of a randomized, controlled comparison. Hum Vaccin Immunother 9:2460–2473
142. Schild GC, Wood JM, Newman RW (1975) A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 52:223–231
143. Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209–3222
144. Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, Giuseppe Del Giudice G, Galli G, Castellino F (2013) Human circulating influenza-CD4+ ICOS1+IL-21 + T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci USA 110:14330–14335
145. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A (2013) Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305–1312
146. Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A (2008) Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 359:1631–1633
147. Sullivan SJ, Jacobson R, Poland GA (2010) Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 9:1127–1133
148. Szakács A, Darin N, Hallböök T (2013) Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80:1315–1321
149. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A (2012) Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30:5761–5769
150. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and RSV. JAMA 289:179–186
151. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340
152. Thompson MG, Shay DK, Zhou H, Bridges CB, Cheng PY, Burns E, Bresee JS, Cox NJ (2010) Estimates of deaths associated with seasonal influenza – United States 1976-2007. MMWR 59:1057–1062
153. Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Goldenthal KL, Kohberger R, Dunkle LM (2013) Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-inwater emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 31(48):5760–5765
154. Tsai T, Giuseppe Del Giudice G, Crucitti A, Weil J, Narasimhan V (2013) Is the adjuvant solely to blame? BMJ 346:f2375. doi:10.1136/bmj.f2375
155. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, Diazgranados C, Landolfi V (2013) Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥ 65 years of age: A randomized, controlled, phase II trial. Vaccine Epub. doi:10.1016/j.vaccine.2013.09.074
156. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-5152
157. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, Bigham M (2013) The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 31:6122-6128
158. van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G (2014) Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population. J Infect Dis 209:12-23
159. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, Podda A (2009a) Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28:563-571
160. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009b) MF59-adjuvanted influenza vaccine (Fluad) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291-6295
161. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406-1416
162. Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R (2012a) Homologous and heterologous antibody responses to a one-year booster dose of an MF59 adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 8:921-928
163. Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M (2012b) Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum Vaccin Immunother 8:1283-1292
164. Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S (2013) Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol 178:1139-1145
165. Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Di Virgilio F, De Gregorio E, Montecucco C, Seubert A (2013) The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA 110:21095-21100
166. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274–280
167. Wilschut J (2009) Influenza vaccines: the virosome concept. Immunol Lett 122:118-121
168. World Health Organization (2012) Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 - conclusions and recommendations. Weekly Epidemiol Rec 87:201-216
169. World Health Organization (2013) http://www.who.int/influenza/vaccines/virus/recommendations/201309_recommendation.pdf. Accessed 23 Dec 2013
170. Zaman A, Holmes TH, Stamatis S, Tu WW, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL (2007) Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 26:107-115